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Abstract The aim of this study was to assess patient-
reported impacts and health-related quality of life (HRQL) of
a 2-year follow-up programme in a large cohort of patients
with stationary, non-functioning, adrenal incidentalomas
(AIs) in western Sweden. 145 patients (mean age 68 years,
62 % females) with AI from a prospective study in western
Sweden were studied. All had completed a 2-year follow-up
programme by November 2007, without evidence of adrenal
malignancy or hormone over-production. To evaluate
patient-reported impacts and HRQL, an eight-item adrenal
incidentaloma impact questionnaire was used retrospec-
tively, together with the hospital anxiety and depression
scale, and the short form-36. There were 111 patients (mean
age 67 years, 63 % females) who responded to the ques-
tionnaire (response rate 77 %). 77 % reported that the AI
diagnosis had caused them to be worried; however, fewer
than 20 % had thought about the lesion often during the
follow-up programme, and only 3 % had felt that it had a
large impact on their current daily life. Only 4 % stated that
the follow-up programme had been a negative experience,
nevertheless 10 % reported a negative impact on their HRQL
during the follow-up programme. Only 2 % stated that release
from follow-up caused worry to any degree. In total, 29 % had
possible anxiety, and 30 % had possible depression, probably
reflecting significant co-morbidity. Possible anxiety corre-
lated with a more negative experience of the follow-up pro-
gramme. In conclusion, the 2-year follow-up programme for
patients with AI was well tolerated. Nonetheless, a small
number remained worried throughout follow-up, suggesting
the need for tailored counselling in individual patients to
ameliorate negative impacts of follow-up.
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Introduction
The purpose of follow-up for patients with incidentally
discovered adrenal lesions (also known as adrenal inciden-
talomas (AIs)) is to identify individuals with malignant or
hormone-producing tumours. However, the majority of
patients with AIs have benign, non-functioning adenomas
that can be managed conservatively [1–6]. Management of
patients with AI imposes a significant burden on health-care
providers, as adrenal lesions are frequent findings on
abdominal computed tomography (CT) and magnetic reso-
nance imaging performed for unrelated reasons. In a survey
in western Sweden, AIs were seen in 4.5 % (range 1.8–7.1 %
between hospitals) of abdominal CT scans [7]. In autopsy
studies, the prevalence of adrenal tumours approaches 7 %
in patients over 70 years of age [8]; hence, as advanced
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cross-sectional imaging is increasingly performed in the
elderly population the detection of AIs can be expected to rise.
Concerns about hormone-production or malignancy
developing in the AI over time provide the rationale for
follow-up programmes, but the extent of follow-up is
debated [9, 10]. In 2002, the U. S. National Institute of
Health published a state-of-the science report on the inci-
dentally discovered adrenal mass, identifying areas of
interest for future studies [11]. The impact of being diag-
nosed with an AI and subsequent follow-up on health-
related quality of life (HRQL) was highlighted as a priority
area. To date, little research has addressed this issue.
We assessed patient-reported impact of a 2-year follow-
up programme and HRQL in a large cohort of patients with
stationary, non-functioning AIs in western Sweden.
Patients and methods
The prospective cohort study of AI in western Sweden
During an 18-month period, all patients with AIs identified
at all radiology departments in western Sweden (serving in-
and out-patient care for 1.7 million inhabitants,) were
prospectively reported and enrolled in a 2-year follow-up
programme. The programme has previously been described
in detail [6, 7]. At detection, the patients were informed
about the study by their attending physician, and referred
for evaluation to one of the local study coordinators
(consultants in internal medicine, endocrinology or endo-
crine surgery) at the Sahlgrenska University Hospital, or
one of the six county hospitals in the region. All patients
received oral and written information about the study and
gave written consent. key points in the written information
were that: a lesion in the adrenal had been incidentally
found; adrenal lesions in most cases are benign and require
no specific treatment, although some represent ‘tumours’
that may require surgery or special medication; the purpose
of follow-up was to detect hormone-producing lesions or
lesions suspicious for malignancy; the follow-up pro-
gramme in the study was compliant with national guide-
lines; and if no signs of hormone production or malignancy
were seen after 2 years, then no further follow-up was
necessary. Additional individualized information was pro-
vided as found necessary.
The follow-up programme
Dedicated adrenal CT was scheduled at 4, 12 and 24 months
as previously described [6]. Clinical and biochemical eval-
uation was scheduled at baseline and after 24 months.
Adrenomedullary function was assessed with 24 h uri-
nary catecholamines and/or metanephrines. Adrenocortical
function was assessed using 24-h urinary-free cortisol (UFC)
and aldosterone (in hypertensive patients, measurements
were taken once again); plasma aldosterone and upright
renin were assessed; and a 1-mg dexamethasone suppression
test (1 mg-DST) was performed. After 24 months, baseline
biochemical work-up was repeated, and all patients under-
went 1 mg-DST. Suppression \60 nmol/L [12] was regar-
ded as normal, while values [138 nmol/L [13] were
regarded as insufficient. In patients with 1 mg-DST cortisol
levels in the range of 60–138 nmol/L, other factors such as
age and co-morbidities were taken into account. Patients
with insufficient suppression at 1 mg-DST were scheduled
for further examinations, including measurement of ACTH,
long-term suppression tests and repeat UFC.
Criteria for conservative management
Criteria for conservative management were radiologically
stationary lesions with benign features [14], and no evi-
dence of hormone over-production (including subclinical
hypercortisolism). Follow-up was terminated after
24 months in patients who fulfilled these criteria, and these
patients were eligible for inclusion in the present study.
Adrenalectomy was considered for patients with unilateral
tumours [3 cm in transaxial diameter, tumours with
interval growth, or tumours with other features suspicious
for malignancy [14] and/or hormone over-production.
Some patients with tumours [3 cm were managed con-
servatively because of benign radiological characteristics,
severe comorbidity, or patient preferences.
Study population
One hundred and forty-five patients (mean age 68 years,
62 % females), who fulfilled the criteria for conservative
management and had completed the 2-year follow-up
programme by November 2007, constituted the study
population. Information on results of biochemical evalua-
tions (UFC and 1 mg-DST cortisol levels), patient’s height
and weight, the presence of diabetes, hypertension, other
cardiovascular disease, and previous history of malignancy
was retrieved from the main study database. Diagnoses of
malignancy were crosschecked against the Swedish
National Cancer Register (http://www.socialstyrelsen.se/
register/halsodataregister/cancerregistret/inenglish).
Development of an adrenal incidentaloma impact
questionnaire (AIIQ)
In order to gain insight into the patients’ experiences of the
follow-up programme, interviews were conducted by one
of the authors (BW) with two randomly selected patients
who had been managed conservatively for AI. Analysis of
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the interview material yielded a dominating theme of
worry–relief. On the basis of these interviews, an 8-item
questionnaire was developed with questions regarding
specific points of interest during the follow-up programme.
Items were constructed to assess: (A) worry, preoccupation
and psychological impact of the diagnosis and follow-up of
the AI, and (B) appraisals of the follow-up programme as
such. Items were framed to cover: (1) the time of diagnosis,
(2) the follow-up period, (3) the time at completion of the
programme, and (4) the time after finishing the programme.
A panel of physicians with experience in treating
AI patients reviewed the items, and the questionnaire was
assessed for face validity (comprehensibility, relevance and
comprehensiveness) by senior nurses at the endocrine unit.
Rationale for using additional instruments
We assumed that the follow-up programme for AI would
affect the patients’ HRQL principally in the area of psy-
chological well-being and mental health, rather than
physical functioning. The Swedish version of the generic
short form-36 (SF-36) [15] was used to assess HRQL. The
SF-36 is a 36-item survey that measures eight domains of
health: physical functioning, role limitations due to phys-
ical health, bodily pain, general health perceptions, vitality,
social functioning, role limitations due to emotional prob-
lems, and mental health. An age- and sex-matched refer-
ence group (n = 145) was randomly drawn from the
Swedish normative database [15]. To evaluate anxiety and
depression, we used the hospital anxiety and depression
scale (HADS) [16]. The HADS consists of two subscales
evaluating anxiety (HADS-A, 7 items) and depression
(HADS-D, 7 items). We used established and validated cut-
off values (\8 non-cases, 8–10 possible cases, and [10
probable cases) for each scale that were proposed by the
developers. Using the cut-off C8, the sensitivity and spec-
ificity for detecting anxiety or depression are both approx-
imately 0.8 [17].
Administration of questionnaires
The three questionnaires, accompanied by a letter signed by
the two principal investigators of the clinical follow-up
study and a stamped return envelope addressed to an
independent institute, were sent by mail on the 15th of
November 2007. Two reminders were used. The second
reminder included a new copy of the questionnaire and
patients who declined to participate were asked to endorse a
reason for not responding. Response alternatives were: To
my knowledge I have not participated in such a programme;
I think the questionnaire is too long; I haven’t time; I don’t
understand the questions; I don’t see the purpose of the
questionnaire; I see no point in answering the questionnaire;
I don’t think the questions are about me; I think the ques-
tions are too intimate; I don’t feel strong enough to answer
the questions; Other reason, please state:….
Statistical analysis
Frequencies were computed for each of the AIIQ items.
Response alternatives were coded from 1 to 5, where
higher values indicate more positive responses. Inter-item
correlations were calculated using Spearman’s rho (rs). An
exploratory factor analysis using Varimax rotation was
performed. The Kaiser rule for factor extraction was
applied. Summated scores of the items comprising the
factors were correlated (rs) with the scores on the HADS
and the SF-36.
Correlations between patient characteristics (age, sex
and co-morbidities), tumour characteristics (tumour size
and location (uni- or bilateral), UFC and 1 mg-DST cor-
tisol levels), and HRQL were performed using Spearman’s
rho. To assess the impact of co-morbidities, a crude co-
morbidity index was used awarding one point each for
hypertension, other cardiovascular disease (e.g. congestive
heart failure and paroxysmal atrial fibrillation), diabetes
and previous or concurrent of extra-adrenal malignancy,
yielding a score from 0 to 4.
Analysis of AIIQ items across different participating
clinical units, and comparisons between AIIQ items and
HADS (non-cases, possible cases and probable cases) were
performed using the Kruskal–Wallis test followed by the
Mann–Whitney U test.
Further comparisons between HADS non-cases, possible
and probable cases, and UFC- and 1 mg-DST cortisol
levels were performed using one-way analysis of variance
(ANOVA), and, for 1 mg-DST, the Chi-square test using
serum cortisol cut-off levels of 50 [18], 60 [12], 83 [19]
and 138 [13] nmol/L. SF-36 data from respondents, and
matched controls was analysed using the Mann–Whitney
U test. Calculations were performed using IBM SPSS
Statistics version 19 (IBM Corporation, Somers, NY).
Results
Patient characteristics and response rate
In total, 111 patients (mean age 67 years; 63 % females)
responded (response rate 77 %). Data were complete for
the AIIQ in 110 cases (109 in items 3 and 8), HADS-
anxiety (HADS-A) in 108 cases, HADS-D in 109 cases and
SF-36 in 108 cases. For characteristics of responders and
non-responders, see Table 1. In 15 of 34 cases, a reason for
not responding was stated: Old age/Questionnaire too
demanding n = 6; Questionnaire not relevant n = 3;
230 Endocrine (2013) 44:228–236
123
Dementia n = 2; No recollection of having participated in
a follow-up programme n = 2; Language problems n = 1;
Matter of principle n = 1. In 19 cases, no explanation was
offered.
Responses to the AIIQ and factor analysis
Responses to the AIIQ are summarized in Fig. 1a, b.
Exploratory factor analysis supported a two-factor model
(eigenvalue[1) explaining 61 % of the variance (Table 2).
AIIQ-items 1, 2, 4 and 5 formed the first factor, labelled
preoccupation with the AI, while the second factor com-
prised items 3 and 6–8, and was labelled evaluation of the
programme as such.
Preoccupation with the AI
The AI diagnosis caused some worry in 85/110 patients
(77 %, item 1, Fig. 1a). During follow-up 20/110 (18 %)
thought about the lesion often (item 2). However, after the
follow-up programme only 3/110 (3 %) patients reported
significant impacts on their everyday life (item 4), and
15/110 (14 %) thought about the lesion sometimes, while
3/110 (3 %) thought about it often, or all the time (item 5).
Evaluation of the programme
Only 2/109 (2 %) reported that the termination of follow-up
had made them feel more worried (item 3, Fig. 1b). In total,
11/110 (10 %) reported that their HRQL had been nega-
tively impacted during the follow-up programme (item 6);
however, only 4/110 (4 %) reported that they had experi-
enced the programme as negative (item 7). The majority of
patients were satisfied with the information received, but
21/109 (19 %) felt that the information about the adrenal
lesion had been insufficient or very insufficient (item 8).
Assessment of information
The patients’ assessment of the information given (item 8)
correlated with the reaction at termination of the pro-
gramme (item 3: rs = 0.33, p = 0.001), impact on every-
day life (item 4: rs = 0.22, p = 0.02), preoccupation during
last month (item 5: rs = 0.29, p = 0.002), and overall
assessment of the programme afterwards (item 7: rs = 0.30,
p = 0.002). No differences in the patients’ assessments
were seen between the participating clinical units.
Responses to the hospital anxiety and depression scale
and SF-36
In total, 12 respondents (11 %) scored as possible cases
and 19 (18 %) as probable cases according to HADS-A.
Sixteen (15 %) scored as possible cases and 16 (15 %) as
probable cases according to HADS-D. There was consid-
erable overlap in cases of anxiety and depression with 21
respondents scoring as possible or probable cases of both
anxiety and depression.
Table 1 Characteristics of patients responding and not responding to
the questionnaires
Responders Non-responders
Subjects, n (%) 111 (100) 34 (100)
Age in years, mean
(median, range)
67 (67, 30–90) 70 (74, 27–89)
Females, n (%) 70 (63) 20 (59)
Bilateral lesions,
n (%)
23 (21) 9 (26)
Size in mm, mean
(median, range)










54.7 ± 63.8 49.6 ± 43.4
Diagnosis at detection*,
n (%)
B Infection 1 (1) 0 (0)
C Malignant
neoplasm
20 (18) 2 (6)
D 00–48 Benign
neoplasm
3 (3) 1 (3)
D 50–89 Blood 1 (1) 0 (0)
E Endocrine 1 (1) 0 (0)
F Mental/behavioural 0 (0) 1 (3)
I Circulatory 11 (10) 1 (3)
J Respiratory 4 (4) 2 (6)
K Digestive 36 (32) 11 (32)
M Musculoskeletal 8 (7) 0 (0)
N Genitourinary 2 (2) 2 (6)
R Symptoms 16 (14) 5 (15)
S Trauma 2 (2) 4 (12)
Y External causes 2 (2) 0 (0)
Z Control after
therapy
4 (4) 5 (15)
Co-existing conditions, n (%)
Hypertension 53 (48) 13 (38)
Cardiovascular
disease
25 (23) 6 (18)
Diabetes mellitus 10 (9) 10 (29)
Hyperlipidemia 13 (12) 1 (3)
Osteoporosis 5 (5) 3 (9)
BMI (kg/m2) [ 25 45 (41) 7 (21)
History of
malignancy
18 (16) 6 (18)
UFC urinary free cortisol, 1 mg-DST 1 mg overnight dexametasone suppression
test
* Results of the work-up for the complaints that led to the incidental discovery of
adrenal lesions, grouped according to the International Classification of Diseases,
version 10 (ICD-10),  Other than hypertension (ICD-10 code I 10.9),  BMI data
missing on 25 responders and 15 non-responders
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Respondents scored significantly lower than norms on
all SF-36 domains, except bodily pain (Fig. 2). This finding
was exclusively accounted for by respondents with one, or
several co-morbidities (previous or concurrent extra-adre-
nal malignancy, cardiovascular disease or diabetes).
Relationships between the AIIQ, HADS and SF-36
The preoccupation factor correlated with the HADS-A
domain (rs = -0.47, p \ 0.001), and the SF-36 domains
mental health (MH, rs = 0.73, p \ 0.001) and vitality (VT,
rs = -0.53, p \ 0.001). Significant differences were seen
between probable cases of anxiety and non-cases (HADS-A
[10 vs.\8) regarding AIIQ items addressing preoccupation
(items 1, 2, 4 and 5, p = 0.002–0.009), with probable cases
scoring 0.61–0.85 units lower than non-cases. They also
reported a greater impact on HRQL during follow-up (item 6,
p = 0.006). However, no differences were seen regarding
worry associated with the termination of the programme
(item 3). Significant differences were also seen between
probable cases of depression and non-cases (HADS-D[10 vs.
\8) regarding impact on everyday life (item 4, p = 0.004),
thoughts about the AI during the last month (item 5,
p = 0.001), and general assessment of the programme after
termination (item 7, p = 0.02), with probable cases of
depression scoring 0.55–0.86 units lower than non-cases.
Relationships between patient and tumour
characteristics and health-related quality of life
Patient age was negatively correlated with the SF-36
domain physical functioning (PF, rs = -0.34, p \ 0.0003).




Item 1 0.843 -0.049
Item 2 0.863 -0.092
Item 3 -0.268 0.755
Item 4 0.683 0.375
Item 5 0.761 0.322
Item 6 0.267 0.577
Item 7 0.107 0.762
Item 8 0.152 0.679
Factor loadings in the final model
Fig. 1 The adrenal incidentaloma impact questionnaire, distribution
of responses for each item. Items grouped according to the factor
analysis. a Preoccupation with the adrenal incidentaloma. b Evalua-
tion of the follow-up programme
b
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Co-morbidity index also correlated with several domains of
SF-36. Weaker, statistically not significant, associations
were seen between co-morbidity and HADS-A (rs = 0.18,
p = 0.06), and HADS-D (rs = 0.18, p = 0.06). No correla-
tions were seen between HRQL and sex, tumour size, location
(uni- or bilateral), UFC or 1 mg-DST cortisol levels, with the
exception of UFC, where higher UFC levels correlated with
better scoring on the SF-36 domain social functioning (SF,
rs = 0.21, p = 0.04) (Table 3). No significant differences
were seen between HADS non-cases, possible and probable
cases with regard to UFC or 1 mg-DST cortisol levels.
Discussion
This study of patient-reported outcomes after completion
of a 2-year follow-up programme for an incidentally dis-
covered adrenal lesion without proven abnormal hormone
production or malignancy suggests that the AI follow-up
programme was well tolerated. Only 4 % experienced the
follow-up programme as negative, and only 2 % reported
increased worry after completing the programme. How-
ever, nearly 30 % were identified as having possible or
probable anxiety or depression, and these patients also had
a more negative experience of the programme.
We identified patients from a follow-up study in western
Sweden [6, 7], in which all patients with AI detected at all
radiology departments in our region (population 1.7 mil-
lion) during an 18-month period were enrolled. The drop-
out rate during follow-up was low [6], and the present
cohort may be regarded as representative for unselected
patients diagnosed with AI in our region. The present study
is, to our knowledge, the first that has attempted to directly
assess patient reported outcomes of a follow-up programme
in a large prospective, population-based series of conser-
vatively managed AI patients. Owecki et al. [20] found
increased anxiety levels and mild depression in a study of
26 polish patients with AI [20]. Brunaud et al. [21] mea-
sured the impact on HRQL of living with an AI using
proxy surgeons’ ratings [21]. Kastelan et al. [22] recently
reported on the HRQL of AI patients seen at a referral
centre compared to an age and sex-matched control group.
In our study, 29 % of the respondents were identified as
possible or probable cases of anxiety (HADS-A C8), and
30 % had possible or probable depression (HADS-D C8).
Corresponding figures have been reported for patients with
chronic diseases, such as coronary heart disease (HADS-A:
30–38 %, HADS-D: 15–50 %) [23–25]; diabetes type 2
(HADS-A: 20 %) [26]; chronic obstructive pulmonary
disease (HADS-A: 27 %, HADS-D: 14 %) [27]; Parkin-
son’s disease (HADS-A: 44 %, HADS-D: 30 %) [28]; and
after curative treatment for head and neck cancer (HADS-
A: 16–28 %, HADS-D: 9–17 %) [29, 30].
Patients with AI are diagnosed as a consequence of
work-up for an unrelated problem, and our study population
has a high prevalence of co-existing morbidity (Table 1).
Using a crude co-morbidity index there was a clear corre-
lation between co-morbidity and worse HRQL in all
physical domains of SF-36 as well as role emotional.
Respondents also scored lower on nearly all domains of SF-
36, reflecting a generally worse HRQL, compared with age
and sex-matched norms from the general population. This is
in agreement with the findings of Kastelan et al. [22].
Patients with probable anxiety (HADS-A [10) reported a
greater impact on their HRQL during follow-up, but were not
significantly more worried about the termination of the pro-
gramme than were non-cases. The potential effect of subclinical
hormone overproduction, e.g. subclinical hypercortisolism, is
an intriguing issue [19]. However, in the present study UFC and
1 mg-DST cortisol levels, adrenal lesion size or bilaterality did
not correlate significantly with any of the domains of AIIQ,
HADS or SF-36. The only exception was the correlation
between UFC levels and the SF-36 domain Social Function,
where higher UFC levels were significantly associated with
better Social Function, most likely a spurious correlation.
HADS-A and HADS-D had a stronger, although not statisti-
cally significant (p = 0.06), relationship with co-morbidity
index. This suggests that comorbidity, rather than a direct effect
of the AI or the follow-up programme as such, was the main
explanation for the levels of anxiety and depression seen in this
Fig. 2 The short form-36—results for respondents versus age and
gender-matched norms legend: means for individual domains for the
respondents (solid line) and an age and sex-matched reference sample
drawn from the Swedish norm database (hatched line). Differences
were statistically significant in all domains (p = 0.00004–0.009),
except BP (p = 0.085). PF physical functioning, RP role physical,
BP bodily pain, GH general health, VT vitality, SF social functioning,
RE role emotional, MH mental health
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patient group. In fact, only four respondents (4 %) rated their
experience of the programme as negative. Still, the patient-
reported measurements of the impact over time of the AI are
retrospective and may be prone to recall bias, and definite
conclusions about cause and effect cannot be drawn. Prospec-
tive studies are needed to study possible associations of anxiety
and depression with tolerance to follow-up algorithms for AI.
Personalised and adequate patient information in a fol-
low-up setting after a pathological test result has been shown
to reduce anxiety [31]. We saw that a negative assessment of
the given information significantly correlated with greater
preoccupation with the AI after the programme. This is in
line with the findings of Bell et al. [32], in a study of psy-
chological adjustment to cervical screening, that patients
reporting a high degree of initial worry at the abnormal test
result were more likely to perceive the information they
were given as inadequate and showed more concern at the
time of the interview. Recently, Van Esch et al. [33] reported
that the personality trait neuroticism and symptoms of
depression and anxiety prior to a diagnosis of breast cancer
were the most important predictors of HRQL 1 and 2 years
after surgery. In a general setting, the perception of risk and
worry are only weakly correlated [34], and patient-associ-
ated factors such as educational level [35, 36], living in
urban or rural areas [36], number of children [36], and
individual coping strategies [37] all correlate with psycho-
logical impacts. Still, focused counselling resources to
patients with a high degree of anxiety at detection of AI may
prevent unnecessary adrenalectomies and decrease negative
impacts of follow-up.
Our study has limitations. Assessments were made only
after completion of the follow-up programme. Hence,
answers are retrospective in nature and no definite infer-
ences regarding causality may be made. Due to the lack of
appropriate instruments the AIIQ was specifically devel-
oped for this study. Although the AIIQ showed good face
validity and construct validity (correlation between the
preoccupation factor and HADS-A), the instrument needs to
be further evaluated. Unfortunately, the Swedish normative
database [15] did not allow matching for co-morbidities in
the SF-36 comparison. Sociodemographic information was
not collected, as it was felt that it might have reduced the
response rate, thus further analyses by potentially relevant
variables were precluded.
In summary, almost all patients in this cohort with
incidentally discovered adrenal lesions reported satisfac-
tion with the follow-up programme and were relieved or
unconcerned when follow-up was ended. Although most
were worried when the AI was detected, only a few
remained worried during follow-up, and for these tailored
counselling is suggested as a means to decrease negative
impacts of follow-up. Overall, a 2-year follow-up pro-
gramme for incidentally discovered adrenal lesions was
well tolerated.
Table 3 Correlation analysis between patient and tumour characteristics and HRQL
Sex Age Comorbidity
index
Uni/bilateral Size UFC 1 mg-DST
AIIQ
Preoccupation 0.083 (0.39) 0.036 (0.71) -0.104 (0.28) 0.044 (0.65) -0.037 (0.70) -0.071 (0.49) 0.16 (0.15)
Evaluation -0.002 (0.98) 0.049 (0.62) 0.013 (0.89) -0.018 (0.85) -0.081 (0.40) -0.015 (0.88) -0.12 (0.26)
HADS
Anxiety -0.066 (0.49) -0.30 (0.76) 0.181 (0.062) 0.098 (0.31) 0.035 (0.72) -0.13 (0.22) -0.12 (0.29)




0.147 (0.13) -0.335 (0.0003)* -0.245 (0.010)* -0.073 (0.45) -0.075 (0.44) -0.031 (0.76) -0.035 (0.75)
Role physical 0.049 (0.612) -0.166 (0.086) -0.275 (0.004)* -0.011 (0.91) -0.078 (0.42) 0.069 (0.50) 0.044 (0.70)
Bodily pain 0.15 (0.12) -0.064 (0.51) -0.219 (0.023)* -0.16 (0.11) -0.103 (0.28) 0.005 (0.96) 0.026 (0.82)
General health 0.095 (0.32) -0.056 (0.56) 0.323 (0.001)* -0.12 (0.23) -0.059 (0.54) 0.073 (0.47) -0.095 (0.39)
Vitality 0.061 (0.53) -0.036) (0.71) -0.105 (0.28) -0.182 (0.058) -0.027 (0.78) 0.037 (0.72) 0.051 (0.65)
Social
functioning
0.035 (0.72) -0.060 (0.53) -0.108 (0.27) -0.11 (0.24) -0.009 (0.93) 0.213 (0.035)* -0.082 (0.46)
Role
emotional
0.15 (0.12) -0.134 (0.16) -0.216 (0.025)* -0.007 (0.95) 0.021 (0.83) 0.15 (0.15) -0.060 (0.59)
Mental health 0.098 (0.31) -0.022 (0.82) -0.092 (0.34) -0.166 (0.086) 0.044 (0.65) 0.13 (0.21) 0.003 (0.98)
Data presented as Spearman’s rho (p value), * p \ 0.05
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